Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider owned 119,763 shares in the company, valued at $4,790,520. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mark Schoenberg also recently made the following trade(s):
- On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00.
- On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The shares were sold at an average price of $27.30, for a total transaction of $142,560.60.
Urogen Pharma Price Performance
Shares of Urogen Pharma stock traded down $1.67 on Friday, hitting $38.56. The company had a trading volume of 1,281,162 shares, compared to its average volume of 656,502. Urogen Pharma has a 52 week low of $13.79 and a 52 week high of $40.35. The company has a market cap of $1.88 billion, a PE ratio of -14.02 and a beta of 1.56. The business has a 50-day simple moving average of $31.28 and a 200-day simple moving average of $24.43.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. On average, equities research analysts predict that Urogen Pharma will post -0.88 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Urogen Pharma
A number of institutional investors and hedge funds have recently modified their holdings of URGN. Paradigm Biocapital Advisors LP lifted its holdings in shares of Urogen Pharma by 6.1% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company's stock valued at $104,773,000 after purchasing an additional 257,564 shares during the last quarter. Morgan Stanley increased its stake in Urogen Pharma by 1.4% in the 4th quarter. Morgan Stanley now owns 2,562,901 shares of the company's stock worth $60,023,000 after purchasing an additional 34,455 shares in the last quarter. Soleus Capital Management L.P. acquired a new stake in Urogen Pharma during the 2nd quarter worth about $29,934,000. SG Americas Securities LLC raised its holdings in Urogen Pharma by 20.3% during the 1st quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company's stock worth $29,808,000 after buying an additional 280,199 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Urogen Pharma during the fourth quarter valued at about $26,350,000. 91.29% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
URGN has been the subject of several research reports. D. Boral Capital reaffirmed a "buy" rating and set a $33.00 target price on shares of Urogen Pharma in a research note on Tuesday, March 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Urogen Pharma in a research report on Monday, April 20th. Oppenheimer reissued an "outperform" rating on shares of Urogen Pharma in a report on Tuesday, June 2nd. LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They set a "buy" rating and a $43.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Urogen Pharma in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Urogen Pharma has a consensus rating of "Moderate Buy" and an average price target of $39.50.
Check Out Our Latest Stock Analysis on URGN
Urogen Pharma Company Profile
(
Get Free Report)
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
